Single mass spectrometry assay targeting m-protein, therapeutic antibodies, and polyclonal immunoglobulins provides unique insight into therapy response kinetics in patients with multiple myeloma
This study shows that MS-MRD is more sensitive than traditional methods and can simultaneously monitor multiple therapeutic antibodies. By analyzing patient samples, the researchers demonstrated the test’s ability to detect early relapse, track treatment response, level of tmAb; enabling more precise monitoring of disease progression and treatment effectiveness in multiple myeloma patients.